Neumora Therapeutics, Inc.NMRA

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company trying to build a pipeline of precision medicines for brain disorders, but its latest quarterly filing reads less like a breakthrough manifesto and more like a cash-burn ledger. The March 2026 10-Q shows the company ended the quarter with $147.1 million in cash and equivalents, down from $193.5 million at the start of the year-a three-month operating cash burn of $46.4 million. That pace would exhaust the current cash pile in roughly eight months if unchecked, a timeline that feels less like “precision” and more like “precision panic.”

The company’s product story centres on NMRA-511, a candidate for neuropsychiatric disorders, but the same filing quietly notes a $1.4 million reduction in programme costs because the Phase 1b study completed early. The pipeline page boasts a broad portfolio of programmes paired with proprietary Precision Phenotype™ strategies, yet the accompanying financials show net losses of $52.9 million in operating income and a net loss attributable to parent shareholders of $53.5 million for the quarter. Diluted earnings per share clocked in at negative $0.30 on 179.9 million diluted shares, while liabilities outstripped equity by $12.5 million. In short, the science may be advancing, but the bank balance is not keeping pace.

The company’s About page promises to “fundamentally change the way people think about the diagnosis and treatment of brain diseases,” a lofty mission that sits awkwardly against the company’s ownership structure. SEC filings disclose 57,529 restricted shares tied to service conditions, a familiar tool for rewarding insiders without immediate dilution. Meanwhile, the cash runway is short, and the balance sheet’s $83.2 million in liabilities versus $70.7 million in shareholders’ equity suggests the company is operating with a thin capital cushion in a sector where capital is oxygen.

Neumora’s product pipeline and company narrative are housed at neumoratx.com, where the visual style suggests a neuroscience unicorn still waiting for its first approval rather than a company that has already burned more than $100 million in the last two years. The site’s imagery leans heavily on stock photography and founder portraits, a common tactic among pre-revenue biotechs, but the numbers tell a different story. The company’s most recent SEC submissions JSON lists filings up to June 2026, including an 8-K filed on 15 June 2026, yet none of the filings change the basic arithmetic: high burn, thin equity, and no revenue.

For those tracking the company through SEC data, the EDGAR index for CIK 0001885522 remains the single source of truth, while the companyfacts JSON provides XBRL disclosures but not a chequebook. The SEC submissions JSON confirms the filing cadence but does not quantify cash needs, and the company’s own pipeline page confirms programme progress without disclosing the cash price tag. Until Neumora reports its first dollar of revenue or raises fresh capital on terms disclosed in a public filing, the gap between the polished pitch and the bank balance will remain the story.